TABLE 3.

Secondary endpoints –‐Summary of comparisons between MLC901 and placebo at BL and change from BL to week W24 (mean +/– SD)

	BL		Change from BL at W24		Comparison
Variable	Placebo	MLC901	Placebo	MLC901	Difference (CI)	P value
ADAS‐Cog	26.3 ± 7.33	26.1 ± 7.6	−0.53 ± 5.35	−1.89 ± 6.54	1.36 (−1.03, 3.75)	.26
MoCA	18.0 ± 5.14	19.2 ± 5.06	1.17 ± 3.03	0.88 ± 2.61	0.30 (−0.80, 1.40)	.59
Digit Cancellation Test	18.0 ± 8.22	16.1 ± 6.72	0.76 ± 5.78	1.63 ± 4.83	−0.87 (−2.94,1.20)	.41
Clock Drawing Test	3.61 ± 1.31	3.65 ± 1.41	0.28 ± 1.28	0.26 ± 1.04	0.02 (−0.43,0.47)	.93
Picture Recall
Immediate	4.17 ± 1.99	4.79 ± 1.88	0/09 ± 1.93	0.09 ± 1.49	0.00 (−0.67,0.99)	.99
Delayed	2.63 ±1.94	3.11 ± 1.89	0.80 ± 1.77	0.77 ± 1.75	0.03 (−0.66,0.72)	.93
Delayed recognition	7.98 ± 2.49	8.32 ± 1.97	0.37 ± 2.25	0.05 ± 1.87	0.31 (−0.49,1.12)	.44
VMR
Immediate	19.7 ± 8.69	19.5 ± 8.85	0.72 ± 5.62	2.16 ± 6.84	−1.44 (−3.93,1.05)	.25
Delayed	9.9 ± 9.04	10.6 ± 9.23	2.62 ± 9.65	3.49 ± 8.73	−0.87 (−4.49,2.75)	.63
Delayed recognition	1.75 ± 1.18	1.67 ± 1.23	0.20 ± 1.59	0.39 ± 1.37	−0.18 (−0.77,0.40)	.54
FAB	12.8 ± 2.95	13.6 ± 2.96	0.70 ± 1.88	0.09 ± 2.18	0.61 (−0.20,1.42)	.14
ADSC‐ADL	38.3 ± 9.5	37.9 ± 10.1	0.6 ± 8.2	0.1 ± 7.4	0.5 (−2.8,3.8)	.75
NPI	3.84 ± 5.83	5.36 ± 8.55	−0.42 ± 6.93	−2.50 ± 5.33	2.08 (−0.52,4.68)	.12
GDS	3.67 ± 3.55	3.35 ± 2.83	−0.09 ± 3.77	−0.74 ± 2.63	0.65 (−0.60,1.90)	.31

Abbreviations: ADAS‐Cog, Alzheimer's Disease Assessment Scale‐Cognitive Subscale; ADCS‐ADL, Alzheimer's Disease Cooperative Study Activities of Daily Living; BL, baseline; CI, confidence interval; FAB, Frontal Assessment Battery; GDS, Geriatric Depression Scale; MoCA, Montreal Cognitive Assessment; NPI, Neuropsychiatry Inventory; VMR, Visual Memory Test; W24, week 24.